ArticleFrontiers in medicine2026
Retinal racemose hemangioma with central retinal vein occlusion: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To highlight that in retinal racemose hemangioma (RRH) complicated by central retinal vein occlusion (CRVO), intravitreal anti-VEGF may only partially resolve macular edema, and timely laser photocoagulation is the decisive adjunct. Case presentation: A 46-year-old female presented with vision loss in the left eye. Fundus examination revealed CRVO and a superotemporal RRH. Optical coherence tomography (OCT) confirmed significant macular edema. After three monthly anti-VEGF injections, hemorrhages subsided partly but macular edema persisted. Subsequently, laser photocoagulation was applied to retinal non-perfusion areas along with continued anti-VEGF therapy, and at 4 months the macular edema had completely resolved, accompanied by a marked improvement in visual acuity. At each subsequent follow-up visit, the patient's ocular status stayed stable, with no evidence of recurrent macular edema. Conclusion: In RRH-associated CRVO, although anti-VEGF therapy effectively managed the acute macular edema, complete resolution required adjunctive laser photocoagulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.